{"filing":{"accession_number":"0001104659-26-095467","cik":"0001751912","ticker":"NGEN","company_name":"NERVGEN PHARMA CORP.","form":"6-K","filing_date":"2026-08-13","report_date":"2026-08-13","primary_document":"tm2623069d1_6k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1751912/000110465926095467/tm2623069d1_6k.htm"},"events":[{"id":27506,"run_id":25076,"accession_number":"0001104659-26-095467","anchor_item_number":"EX-99.3","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.92,"summary":"This exhibit is a press release announcing NervGen's second quarter 2026 financial results, including cash position (C$86.8 million), R\u0026D and G\u0026A expenses, and net loss (C$29.2 million). The document explicitly states \"NervGen Reports Second Quarter 2026 Financial Results\" and provides detailed quarterly financial metrics. While the release also includes business updates (Phase 3 RESTORE study progress, leadership appointments), the primary disclosure is the quarterly earnings announcement, which is material to investors assessing the company's financial condition and runway.","company_name":"NERVGEN PHARMA CORP.","ticker":"NGEN","filing_date":"2026-08-13","form":"6-K","submitted_at":null,"items":[{"id":29080,"accession_number":"0001104659-26-095467","item_number":"EX-99.3","item_title":"tm2623069d1_ex99-3.htm","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"This exhibit is a press release announcing NervGen's second quarter 2026 financial results, including cash position (C$86.8 million), R\u0026D and G\u0026A expenses, and net loss (C$29.2 million). The document explicitly states \"NervGen Reports Second Quarter 2026 Financial Results\" and provides detailed quarterly financial metrics. While the release also includes business updates (Phase 3 RESTORE study progress, leadership appointments), the primary disclosure is the quarterly earnings announcement, which is material to investors assessing the company's financial condition and runway.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-13T11:32:49.607018+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":29078,"accession_number":"0001104659-26-095467","item_number":"EX-99.1","item_title":"tm2623069d1_ex99-1.htm","event_type":"periodic_interim","event_domain":"periodic","is_material":false,"confidence":0.95,"reasoning":"This exhibit is a condensed consolidated interim financial statement for NervGen Pharma Corp. covering the three and six months ended June 30, 2026 and 2025, prepared in accordance with IAS 34 and IFRS. It is a periodic interim financial report (the foreign-issuer equivalent of a 10-Q), not a discrete event or earnings release. The document explicitly states it is \"unaudited\" and includes balance sheets, statements of loss and comprehensive loss, cash flows, and changes in shareholders' equity—the standard components of an interim financial filing. While the company is pre-revenue and burning cash, this is a routine periodic disclosure, not a material event requiring investor action.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-13T11:32:49.607018+00:00","company_name":"NERVGEN PHARMA CORP.","ticker":"NGEN","filing_date":"2026-08-13"},{"id":29079,"accession_number":"0001104659-26-095467","item_number":"EX-99.2","item_title":"tm2623069d1_ex99-2.htm","event_type":"periodic_quarterly","event_domain":"periodic","is_material":false,"confidence":0.95,"reasoning":"This exhibit is a Management's Discussion and Analysis (MD\u0026A) for the three and six months ended June 30, 2026, which is a periodic quarterly financial report. The document explicitly states it covers \"the three and six months ended June 30, 2026\" and is dated August 13, 2026. MD\u0026A is a standard component of quarterly financial filings (equivalent to a 10-Q for foreign private issuers). This is the periodic report itself, not a discrete event announcement, and should be deferred for separate processing rather than classified as an earnings release or other event.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-13T11:32:49.607018+00:00","company_name":"NERVGEN PHARMA CORP.","ticker":"NGEN","filing_date":"2026-08-13"},{"id":29080,"accession_number":"0001104659-26-095467","item_number":"EX-99.3","item_title":"tm2623069d1_ex99-3.htm","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"This exhibit is a press release announcing NervGen's second quarter 2026 financial results, including cash position (C$86.8 million), R\u0026D and G\u0026A expenses, and net loss (C$29.2 million). The document explicitly states \"NervGen Reports Second Quarter 2026 Financial Results\" and provides detailed quarterly financial metrics. While the release also includes business updates (Phase 3 RESTORE study progress, leadership appointments), the primary disclosure is the quarterly earnings announcement, which is material to investors assessing the company's financial condition and runway.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-13T11:32:49.607018+00:00","company_name":"NERVGEN PHARMA CORP.","ticker":"NGEN","filing_date":"2026-08-13"},{"id":29081,"accession_number":"0001104659-26-095467","item_number":"EX-99.4","item_title":"tm2623069d1_ex99-4.htm","event_type":"periodic_interim","event_domain":"periodic","is_material":false,"confidence":0.95,"reasoning":"This exhibit is a Form 52-109F2 certification of interim filings by the CEO, certifying the interim financial report and MD\u0026A for the period ended June 30, 2026. It is a procedural certification document accompanying an interim financial report, not a discrete event. The certification itself is a routine administrative disclosure required under Canadian securities law (National Instrument 52-109) and does not constitute a material event to investors; it is part of the periodic interim financial reporting process.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-13T11:32:49.607018+00:00","company_name":"NERVGEN PHARMA CORP.","ticker":"NGEN","filing_date":"2026-08-13"},{"id":29082,"accession_number":"0001104659-26-095467","item_number":"EX-99.5","item_title":"tm2623069d1_ex99-5.htm","event_type":"periodic_interim","event_domain":"periodic","is_material":false,"confidence":0.95,"reasoning":"This exhibit is a Form 52-109F2 certification of interim filings by the CFO, certifying the interim financial report and MD\u0026A for the period ended June 30, 2026. It is a routine regulatory certification accompanying an interim financial report, not a discrete event. The certification itself is administrative and does not disclose new material information beyond what appears in the underlying interim financial statements and MD\u0026A.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-13T11:32:49.607018+00:00","company_name":"NERVGEN PHARMA CORP.","ticker":"NGEN","filing_date":"2026-08-13"}]}